Apyx Medical Corporation (NASDAQ: APYX) Stock Competitors & Peer Comparison
See APYX's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Specialties Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for APYX and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| APYX | $2.90 | +0.35% | 122.1M | -14.50 | -$0.20 | N/A |
| ALC | $66.03 | -0.78% | 32.2B | 20.77 | $3.18 | +0.54% |
| STE | $210.76 | -0.80% | 20.5B | 20.22 | $10.42 | +1.22% |
| QDEL | $11.78 | -3.05% | 803.3M | 8.79 | $1.34 | N/A |
| MLAB | $120.87 | -0.03% | 676.4M | 12.20 | $9.91 | +0.53% |
| BWAY | $13.93 | +0.14% | 546.4M | 35.39 | $0.39 | N/A |
| MASS | $9.52 | +1.82% | 390.6M | -15.87 | -$0.60 | N/A |
| SI | $18.53 | -3.04% | 381M | -10.62 | -$1.73 | N/A |
| MOBI | $10.01 | -2.34% | 332.8M | -0.53 | -$18.78 | N/A |
| ANIK | $20.86 | -0.62% | 279.2M | 42.57 | $0.49 | N/A |
Stock Comparison
Alcon Inc. (NYSE: ALC)
APYX vs ALC Comparison September 2026
Apyx Medical Corporation (NASDAQ: APYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 122.1M. In comparison, ALC has a market cap of 32.2B. Regarding current trading prices, APYX is priced at $2.90 on the NASDAQ, while ALC trades at $66.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -14.50, whereas ALC's P/E ratio is 20.77. In terms of profitability, APYX's ROE is -0.79%, compared to ALC's ROE of +0.03%. Regarding short-term risk, APYX is more volatile compared to ALC. This indicates higher risk in terms of short-term price fluctuations for APYX.Check ALC's competition here
STERIS plc (NYSE: STE)
APYX vs STE Comparison September 2026
Apyx Medical Corporation (NASDAQ: APYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 122.1M. In comparison, STE has a market cap of 20.5B. Regarding current trading prices, APYX is priced at $2.90 on the NASDAQ, while STE trades at $210.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -14.50, whereas STE's P/E ratio is 20.22. In terms of profitability, APYX's ROE is -0.79%, compared to STE's ROE of +0.11%. Regarding short-term risk, APYX is more volatile compared to STE. This indicates higher risk in terms of short-term price fluctuations for APYX.Check STE's competition here
QuidelOrtho Corporation (NASDAQ: QDEL)
APYX vs QDEL Comparison September 2026
Apyx Medical Corporation (NASDAQ: APYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 122.1M. In comparison, QDEL has a market cap of 803.3M. Regarding current trading prices, APYX is priced at $2.90 on the NASDAQ, while QDEL trades at $11.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -14.50, whereas QDEL's P/E ratio is 8.79. In terms of profitability, APYX's ROE is -0.79%, compared to QDEL's ROE of -0.55%. Regarding short-term risk, APYX is more volatile compared to QDEL. This indicates higher risk in terms of short-term price fluctuations for APYX.Check QDEL's competition here
Mesa Laboratories, Inc. (NASDAQ: MLAB)
APYX vs MLAB Comparison September 2026
Apyx Medical Corporation (NASDAQ: APYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 122.1M. In comparison, MLAB has a market cap of 676.4M. Regarding current trading prices, APYX is priced at $2.90 on the NASDAQ, while MLAB trades at $120.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -14.50, whereas MLAB's P/E ratio is 12.20. In terms of profitability, APYX's ROE is -0.79%, compared to MLAB's ROE of +0.03%. Regarding short-term risk, APYX is more volatile compared to MLAB. This indicates higher risk in terms of short-term price fluctuations for APYX.Check MLAB's competition here
BrainsWay Ltd. (NASDAQ: BWAY)
APYX vs BWAY Comparison September 2026
Apyx Medical Corporation (NASDAQ: APYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 122.1M. In comparison, BWAY has a market cap of 546.4M. Regarding current trading prices, APYX is priced at $2.90 on the NASDAQ, while BWAY trades at $13.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -14.50, whereas BWAY's P/E ratio is 35.39. In terms of profitability, APYX's ROE is -0.79%, compared to BWAY's ROE of +0.13%. Regarding short-term risk, APYX is more volatile compared to BWAY. This indicates higher risk in terms of short-term price fluctuations for APYX.Check BWAY's competition here
908 Devices Inc. (NASDAQ: MASS)
APYX vs MASS Comparison September 2026
Apyx Medical Corporation (NASDAQ: APYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 122.1M. In comparison, MASS has a market cap of 390.6M. Regarding current trading prices, APYX is priced at $2.90 on the NASDAQ, while MASS trades at $9.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -14.50, whereas MASS's P/E ratio is -15.87. In terms of profitability, APYX's ROE is -0.79%, compared to MASS's ROE of -0.25%. Regarding short-term risk, APYX is more volatile compared to MASS. This indicates higher risk in terms of short-term price fluctuations for APYX.Check MASS's competition here
Shoulder Innovations, Inc. (NYSE: SI)
APYX vs SI Comparison September 2026
Apyx Medical Corporation (NASDAQ: APYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 122.1M. In comparison, SI has a market cap of 381M. Regarding current trading prices, APYX is priced at $2.90 on the NASDAQ, while SI trades at $18.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -14.50, whereas SI's P/E ratio is -10.62. In terms of profitability, APYX's ROE is -0.79%, compared to SI's ROE of -0.26%. Regarding short-term risk, APYX is more volatile compared to SI. This indicates higher risk in terms of short-term price fluctuations for APYX.Check SI's competition here
Mobia Medical, Inc. Common Stock (NASDAQ: MOBI)
APYX vs MOBI Comparison September 2026
Apyx Medical Corporation (NASDAQ: APYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 122.1M. In comparison, MOBI has a market cap of 332.8M. Regarding current trading prices, APYX is priced at $2.90 on the NASDAQ, while MOBI trades at $10.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -14.50, whereas MOBI's P/E ratio is -0.53. In terms of profitability, APYX's ROE is -0.79%, compared to MOBI's ROE of -15.96%. Regarding short-term risk, APYX is more volatile compared to MOBI. This indicates higher risk in terms of short-term price fluctuations for APYX.Check MOBI's competition here
Anika Therapeutics, Inc. (NASDAQ: ANIK)
APYX vs ANIK Comparison September 2026
Apyx Medical Corporation (NASDAQ: APYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 122.1M. In comparison, ANIK has a market cap of 279.2M. Regarding current trading prices, APYX is priced at $2.90 on the NASDAQ, while ANIK trades at $20.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -14.50, whereas ANIK's P/E ratio is 42.57. In terms of profitability, APYX's ROE is -0.79%, compared to ANIK's ROE of -0.03%. Regarding short-term risk, APYX is more volatile compared to ANIK. This indicates higher risk in terms of short-term price fluctuations for APYX.Check ANIK's competition here
Standard BioTools Inc. (NASDAQ: LAB)
APYX vs LAB Comparison September 2026
Apyx Medical Corporation (NASDAQ: APYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 122.1M. In comparison, LAB has a market cap of 273.8M. Regarding current trading prices, APYX is priced at $2.90 on the NASDAQ, while LAB trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -14.50, whereas LAB's P/E ratio is -9.99. In terms of profitability, APYX's ROE is -0.79%, compared to LAB's ROE of -0.18%. Regarding short-term risk, APYX is more volatile compared to LAB. This indicates higher risk in terms of short-term price fluctuations for APYX.Check LAB's competition here
Edap Tms S.a. (NASDAQ: EDAP)
APYX vs EDAP Comparison September 2026
Apyx Medical Corporation (NASDAQ: APYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 122.1M. In comparison, EDAP has a market cap of 178.2M. Regarding current trading prices, APYX is priced at $2.90 on the NASDAQ, while EDAP trades at $4.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -14.50, whereas EDAP's P/E ratio is -5.80. In terms of profitability, APYX's ROE is -0.79%, compared to EDAP's ROE of -3.13%. Regarding short-term risk, APYX is more volatile compared to EDAP. This indicates higher risk in terms of short-term price fluctuations for APYX.Check EDAP's competition here
Trinity Biotech plc (NASDAQ: TRIB)
APYX vs TRIB Comparison September 2026
Apyx Medical Corporation (NASDAQ: APYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 122.1M. In comparison, TRIB has a market cap of 156.7M. Regarding current trading prices, APYX is priced at $2.90 on the NASDAQ, while TRIB trades at $7.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -14.50, whereas TRIB's P/E ratio is -0.13. In terms of profitability, APYX's ROE is -0.79%, compared to TRIB's ROE of +0.68%. Regarding short-term risk, APYX is less volatile compared to TRIB. This indicates lower risk in terms of short-term price fluctuations for APYX.Check TRIB's competition here
Nyxoah S.A. (NASDAQ: NYXH)
APYX vs NYXH Comparison September 2026
Apyx Medical Corporation (NASDAQ: APYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 122.1M. In comparison, NYXH has a market cap of 154.1M. Regarding current trading prices, APYX is priced at $2.90 on the NASDAQ, while NYXH trades at $1.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -14.50, whereas NYXH's P/E ratio is -0.61. In terms of profitability, APYX's ROE is -0.79%, compared to NYXH's ROE of -1.80%. Regarding short-term risk, APYX is more volatile compared to NYXH. This indicates higher risk in terms of short-term price fluctuations for APYX.Check NYXH's competition here
SkinHealth Systems Inc. (NASDAQ: SKIN)
APYX vs SKIN Comparison September 2026
Apyx Medical Corporation (NASDAQ: APYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 122.1M. In comparison, SKIN has a market cap of 90.7M. Regarding current trading prices, APYX is priced at $2.90 on the NASDAQ, while SKIN trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -14.50, whereas SKIN's P/E ratio is -3.18. In terms of profitability, APYX's ROE is -0.79%, compared to SKIN's ROE of -0.48%. Regarding short-term risk, APYX is more volatile compared to SKIN. This indicates higher risk in terms of short-term price fluctuations for APYX.Check SKIN's competition here
DarioHealth Corp. (NASDAQ: DRIO)
APYX vs DRIO Comparison September 2026
Apyx Medical Corporation (NASDAQ: APYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 122.1M. In comparison, DRIO has a market cap of 52.1M. Regarding current trading prices, APYX is priced at $2.90 on the NASDAQ, while DRIO trades at $6.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -14.50, whereas DRIO's P/E ratio is -1.22. In terms of profitability, APYX's ROE is -0.79%, compared to DRIO's ROE of +1.04%. Regarding short-term risk, APYX is more volatile compared to DRIO. This indicates higher risk in terms of short-term price fluctuations for APYX.Check DRIO's competition here
Spectral AI, Inc. (NASDAQ: MDAI)
APYX vs MDAI Comparison September 2026
Apyx Medical Corporation (NASDAQ: APYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 122.1M. In comparison, MDAI has a market cap of 50.9M. Regarding current trading prices, APYX is priced at $2.90 on the NASDAQ, while MDAI trades at $1.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -14.50, whereas MDAI's P/E ratio is -3.56. In terms of profitability, APYX's ROE is -0.79%, compared to MDAI's ROE of +1.21%. Regarding short-term risk, APYX is more volatile compared to MDAI. This indicates higher risk in terms of short-term price fluctuations for APYX.Check MDAI's competition here
HeartBeam, Inc. (NASDAQ: BEAT)
APYX vs BEAT Comparison September 2026
Apyx Medical Corporation (NASDAQ: APYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 122.1M. In comparison, BEAT has a market cap of 22.6M. Regarding current trading prices, APYX is priced at $2.90 on the NASDAQ, while BEAT trades at $0.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -14.50, whereas BEAT's P/E ratio is -0.80. In terms of profitability, APYX's ROE is -0.79%, compared to BEAT's ROE of -6.87%. Regarding short-term risk, APYX is more volatile compared to BEAT. This indicates higher risk in terms of short-term price fluctuations for APYX.Check BEAT's competition here
HeartBeam, Inc. (NASDAQ: BEATW)
APYX vs BEATW Comparison September 2026
Apyx Medical Corporation (NASDAQ: APYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 122.1M. In comparison, BEATW has a market cap of 11.3M. Regarding current trading prices, APYX is priced at $2.90 on the NASDAQ, while BEATW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -14.50, whereas BEATW's P/E ratio is -0.03. In terms of profitability, APYX's ROE is -0.79%, compared to BEATW's ROE of -6.87%. Regarding short-term risk, APYX is less volatile compared to BEATW. This indicates lower risk in terms of short-term price fluctuations for APYX.Check BEATW's competition here
WORK Medical Technology Group Ltd. Class A (NASDAQ: WOK)
APYX vs WOK Comparison September 2026
Apyx Medical Corporation (NASDAQ: APYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 122.1M. In comparison, WOK has a market cap of 4.6M. Regarding current trading prices, APYX is priced at $2.90 on the NASDAQ, while WOK trades at $1.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -14.50, whereas WOK's P/E ratio is N/A. In terms of profitability, APYX's ROE is -0.79%, compared to WOK's ROE of -0.19%. Regarding short-term risk, APYX is more volatile compared to WOK. This indicates higher risk in terms of short-term price fluctuations for APYX.Check WOK's competition here
QTREX Quantum Ltd. Warrant (NASDAQ: QTEXW)
APYX vs QTEXW Comparison September 2026
Apyx Medical Corporation (NASDAQ: APYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 122.1M. In comparison, QTEXW has a market cap of 3.5M. Regarding current trading prices, APYX is priced at $2.90 on the NASDAQ, while QTEXW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -14.50, whereas QTEXW's P/E ratio is -0.01. In terms of profitability, APYX's ROE is -0.79%, compared to QTEXW's ROE of N/A. Regarding short-term risk, APYX is less volatile compared to QTEXW. This indicates lower risk in terms of short-term price fluctuations for APYX.Check QTEXW's competition here
iTonic Holdings Ltd. (NASDAQ: ITOC)
APYX vs ITOC Comparison September 2026
Apyx Medical Corporation (NASDAQ: APYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 122.1M. In comparison, ITOC has a market cap of 2.8M. Regarding current trading prices, APYX is priced at $2.90 on the NASDAQ, while ITOC trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -14.50, whereas ITOC's P/E ratio is -0.98. In terms of profitability, APYX's ROE is -0.79%, compared to ITOC's ROE of -0.94%. Regarding short-term risk, APYX is more volatile compared to ITOC. This indicates higher risk in terms of short-term price fluctuations for APYX.Check ITOC's competition here
ENvue Medical, Inc. (NASDAQ: FEED)
APYX vs FEED Comparison September 2026
Apyx Medical Corporation (NASDAQ: APYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 122.1M. In comparison, FEED has a market cap of 2.8M. Regarding current trading prices, APYX is priced at $2.90 on the NASDAQ, while FEED trades at $3.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -14.50, whereas FEED's P/E ratio is -0.03. In terms of profitability, APYX's ROE is -0.79%, compared to FEED's ROE of -0.60%. Regarding short-term risk, APYX is more volatile compared to FEED. This indicates higher risk in terms of short-term price fluctuations for APYX.Check FEED's competition here
Tivic Health Systems, Inc. (NASDAQ: TIVC)
APYX vs TIVC Comparison September 2026
Apyx Medical Corporation (NASDAQ: APYX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 122.1M. In comparison, TIVC has a market cap of 279.2K. Regarding current trading prices, APYX is priced at $2.90 on the NASDAQ, while TIVC trades at $0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -14.50, whereas TIVC's P/E ratio is -0.04. In terms of profitability, APYX's ROE is -0.79%, compared to TIVC's ROE of -1.65%. Regarding short-term risk, APYX is less volatile compared to TIVC. This indicates lower risk in terms of short-term price fluctuations for APYX.Check TIVC's competition here